Use outcome assessment and follow-up to evaluate response

The manuals converge on the need to track outcomes over time rather than relying on immediate impressions alone. Across the extracts, they describe baseline and repeated follow-up assessments after dosing or during treatment, with comparisons between pre and post treatment status to judge symptom change, remission, or sustained benefit. Several sources also link outcome monitoring to ongoing clinical evaluation, including adjustment or continuation of care. They also converge on using structured measures where possible, especially for anxiety, depression, pain, and substance use outcomes. The extracts include repeated symptom monitoring over hours, days, weeks, months, and in one case up to 12 months, showing that follow-up length varies by manual but the underlying competency is consistent, namely documenting whether benefit appears quickly, persists, or wanes. The manuals differ in what they measure and how long they follow people. Some focus on acute and short-term psychedelic response after 5-MeO-DMT or ayahuasca, others on longer follow-up for LSD, ketamine-assisted psychotherapy, or ibogaine outcomes. They also differ in outcome domain, with some centred on anxiety or depression, others on pain, PTSD, abstinence, relapse risk, and social or family functioning.